Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

(2018) N C Turner et al.   ANNALS OF ONCOLOGY

Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study

(2018) Norikazu Masuda et al.   CANCER SCIENCE

Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA‐3 Results

(2017) Sibylle Loibl et al.   ONCOLOGIST

Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients

(2016) Kenji Tamura et al.   CANCER SCIENCE

PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

(2016) Charlotte Fribbens et al.   JOURNAL OF CLINICAL ONCOLOGY

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)

(2016) Sunil Verma et al.   ONCOLOGIST

Female Breast Cancer Incidence Among Asian and Western Populations: More Similar Than Expected

(2015) Hyuna Sung et al.   JNCI-Journal of the National Cancer Institute

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Female Breast Cancer Incidence Among Asian and Western Populations: More Similar Than Expected

(2015) Hyuna Sung et al.   JNCI-Journal of the National Cancer Institute

Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)

(2010) S. Ohno et al.   ANNALS OF ONCOLOGY